PI3K/Akt/mTOR Signaling
- Akt(129)
- AMPK(75)
- CK2(11)
- DNA-PK(25)
- GSK-3(76)
- MELK(7)
- mTOR(118)
- PI3K(227)
- PI4K(15)
- PDK-1(18)
- PIKfyve(4)
- PKB(1)
- S6 Kinase(12)
Products for PI3K/Akt/mTOR Signaling
- Cat.No. Product Name Information
- GC13468 BI-D1870 P90 RSK inhibitor,ATP-competitive and cell-permeable
-
GC10752
Bikinin
GSK3 inhibitor and Brassinosteroid activator
-
GC14233
BIO-acetoxime
GSK-3α/β inhibitor
- GC38892 BIP-135 BIP-135 is a potent and selective ATP-competitive GSK-3 inhibitor, with IC50s of 16 nM and 21 nM for GSK-3α and GSK-3β, respectively.
- GC12982 BIX 02565 RSK2 inhibitor
- GC11931 BKM120 An inhibitor of class I PI3K isoforms
- GC65534 Boc-L-cyclobutylglycine Boc-L-cyclobutylglycine is a glycine derivative that can be used for PI3K inhibitor synthesis.
- GC65367 Borussertib Borussertib is a covalent-allosteric and first-in-class inhibitor of protein kinase Akt, with an IC50 of 0.8 nM and a Ki of 2.2 nM for Aktwt.
- GC32163 BQR-695 (NVP-BQR695) BQR-695 (NVP-BQR695) is a PI4KIIIβ inhibitor with IC50s of 80 and 3.5 nM for human PI4KIIIβ and Plasmodium variant of PI4KIIIβ, respectively.
- GC42974 Brassinin Brassinin (BSN) is a phytoalexin isolated from B.
- GC39181 BRD0705 BRD0705 is a potent, paralog selective and orally active GSK3α inhibitor with an IC50 of 66 nM and a Kd of 4.8 μM. BRD0705 displays increased selectivity for GSK3α (8-fold) versus GSK3β (IC50 of 515 nM). BRD0705 can be used for acute myeloid leukemia (AML) research.
- GC62875 BRD3731 BRD3731 is a selective GSK3β inhibitor, with IC50s of 15 nM and 215 nM for GSK3β and GSK3α, respectively.
- GC30156 Brevianamide F (Cyclo(L-Pro-L-Trp)) Brevianamide F (Cyclo(L-Pro-L-Trp)) (Cyclo(L-Pro-L-Trp)) is a mycotoxin isolated from Colletotrichum gloeosporioides, with antibacterial activity.
- GC42987 Buformin (hydrochloride) Buformin is a biguanide derivative with antihyperglycemic activity.
- GC16818 BX-912 PDK1 inhibitor,potent and ATP-competitive
- GC15615 BX517(PDK1 inhibitor2) BX517(PDK1 inhibitor2) is a potent and selective inhibitor of PDK1 with IC50 of 6 nM.
- GC11573 BX795 A multi-kinase inhibitor
-
GC16462
BYL-719
BYL719 (Alpelisib) is a selective PI3Kɑ inhibitor.
- GC13396 CAL-101 (Idelalisib, GS-1101) A selective PI3K p110δ inhibitor
- GC35579 CAL-130 CAL-130 is a PI3Kδ and PI3Kγ inhibitor with IC50s of 1.3 and 6.1 nM, respectively.
- GC11135 CAL-130 Hydrochloride
- GC35580 CAL-130 Racemate CAL-130 Racemate is the racemate of CAL-130. CAL-130 Racemate is a PI3Kδ inhibitor.
-
GC43149
CAY10404
Many non-steroidal anti-inflammatory drugs (NSAIDs) are potent but non-selective inhibitors of both COX-1 and COX-2 in humans.
- GC14318 CAY10505 Potent PI3Kγ inhibitor
- GC18322 CAY10567 Akt1, 2, and 3 are serine/threonine protein kinases in the phosphatidylinositol 3 (PI3)-kinase signalling pathway that play a critical role in the regulation of cell proliferation and survival.
- GC18884 CAY10626 CAY10626 is a PI3Kα/mTOR dual kinase inhibitor. CAY10626 has IC50s of 0.9, 0.6 nM for PI3Kα and mTOR, respectively. CAY10626 can be used for the research of cancer.
- GC40650 CAY10706 CAY10706 is a ligustrazine-curcumin hybrid that promotes intracellular reactive oxygen species accumulation preferentially in lung cancer cells.
- GC30229 Cbz-B3A Cbz-B3A is a potent and selective inhibitor of mTORC1 signaling that appear to bind to ubiquilins 1, 2, and 4, and Cbz-B3A inhibits the phosphorylation of eIF4E-binding protein 1 (4EBP1).
- GC16654 CC-115 mTOR/DNA-PK inhibitor
- GC34121 CC-115 hydrochloride CC-115 hydrochloride is a potent and dual DNA-PK and mTOR kinase inhibitor with IC50s of 13 nM and 21 nM, respectively. CC-115 blocks both mTORC1 and mTORC2 signaling.
- GC13648 CC-223 CC-223 (CC-223) is a potent, selective, and orally bioavailable inhibitor of mTOR kinase, with an IC50 value for mTOR kinase of 16 nM. CC-223 inhibits both mTORC1 and mTORC2.
- GC65944 CC214-2 CC214-2 is a potent and dual inhibitor of mTORC1/mTORC2. Mycobacterium tuberculosis modulates mammalian target of rapamycin (mTOR) signaling to impede autophagy. CC214-2 has the potential to shorten the duration of TB.
- GC15864 CCT128930 AKT inhibitor
- GC63539 CCT128930 hydrochloride CCT128930 hydrochloride is a potent and selective inhibitor of AKT (IC50=6 nM). CCT128930 hydrochloride has 28-fold selectivity over the closely related PKA kinase (IC50=168 nM) through the targeting of Met282 of AKT (Met173 of PKA-AKT chimera), as well as 20-fold selectivity over p70S6K (IC50=120 nM). CCT128930 hydrochloride induces cell cycle arrest, DNA damage, and autophagy. Antitumor activity.
- GC35651 Cenisertib Cenisertib (AS-703569) is an ATP-competitive multi-kinase inhibitor that blocks the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3. Cenisertib induces major growth-inhibitory effects by blocking the activity of several different molecular targets in neoplastic mast cells (MC). Cenisertib inhibits tumor growth in xenograft models of pancreatic, breast, colon, ovarian, and lung tumors and leukemia.
- GC10070 CGS 15943 adenosine receptor antagonist
- GC11868 CH5132799 Class I PI3K inhibitor
- GC15642 CHIR 99021 trihydrochloride Laduviglusib (CHIR-99021) trihydrochloride is a potent and selective GSK-3α/β inhibitor with IC50s of 10 nM and 6.7 nM. CHIR 99021 trihydrochloride shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. CHIR 99021 trihydrochloride is also a potent Wnt/β-catenin signaling pathway activator. CHIR 99021 trihydrochloride enhances mouse and human embryonic stem cells self-renewal. CHIR 99021 trihydrochloride induces autophagy.
- GC12176 CHIR-98014 GSK-3β inhibitor,selective and ATP-competitive
-
GC16702
CHIR-99021 (CT99021)
A selective GSK3 inhibitor
- GC17153 CHIR-99021 (CT99021) HCl Laduviglusib (CHIR-99021) monohydrochloride is a potent and selective GSK-3α/β inhibitor with IC50s of 10 nM and 6.7 nM. CHIR-99021 (CT99021) HCl shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. CHIR-99021 (CT99021) HCl is also a potent Wnt/β-catenin signaling pathway activator. CHIR-99021 (CT99021) HCl enhances mouse and human embryonic stem cells self-renewal. CHIR-99021 (CT99021) HCl induces autophagy.
- GC32942 CHIR-99021 monohydrochloride (CT99021 monohydrochloride)
- GC49392 CHIR98024 A GSK3 inhibitor
- GC31383 Chitosan oligosaccharide COS
- GC65969 CHMFL-PI3KD-317 CHMFL-PI3KD-317 is a highly potent, selective and orally active PI3Kδ inhibitor, with an IC50 of 6 nM, and exhibits over 10-1500 fold selectivity over other class I, II and III PIKK family isoforms, such as PI3Kα (IC50, 62.6 nM), PI3Kβ (IC50, 284 nM), PI3Kγ (IC50, 202.7 nM), PIK3C2A (IC50, >10000 nM), PIK3C2B (IC50, 882.3 nM), VPS34 (IC50, 1801.7 nM), PI4KIIIA (IC50, 574.1 nM) and PI4KIIIB (IC50, 300.2 nM). CHMFL-PI3KD-317 inhibits PI3Kδ-mediated Akt T308 phosphorylation in Raji cells, with an EC50 of 4.3 nM. CHMFL-PI3KD-317 has antiproliferative effects on cancer cells.
- GC12532 CHPG mGlu5 metabotropic glutamate receptor agonist
- GC17963 CHPG Sodium salt mGlu5 agonist
- GN10222 Cimigenol-3-O-α-L-arabinoside
- GC14693 CMK
- GC19109 CNX-1351 CNX-1351 is a potent and isoform-selective targeted covalent PI3Kα inhibitor with IC50 of 6.8 nM.
- GC62548 COH-SR4 COH-SR4 is an AMPK activator.
- GC43302 Compound 23 An inhibitor of mTOR
- GC43303 Compound 28 An inhibitor of mTOR
- GC10812 Compound 401 DNA-PK and mTOR inhibitor
- GC46123 Comprehensive Kinase Screening Library For screening of a variety of kinase inhibitors
- GC13176 CP21R7 GSK3β inhibitor
- GC35747 Crebanine Crebanine, an alkaloid from Stephania venosa, induces G1 arrest and apoptosis in human cancer cells.
- GC17690 Cromolyn sodium Mast cell membrane stabilizer
- GC30582 Crosstide Crosstide is a peptide analog of glycogen synthase kinase α/β fusion protein sequence which is a substrate for Akt.
- GC52387 Crosstide (trifluoroacetate salt) A peptide substrate for Akt
- GC12115 CUDC-907 A dual inhibitor of HDACs and PI3Ks
- GC13037 CX-4945 (Silmitasertib) CX-4945 (Silmitasertib) (CX-4945) is an orally bioavailable, highly selective and potent CK2 inhibitor, with IC50 values of 1 nM against CK2α and CK2α'.
- GC11325 CX-4945 sodium salt CX-4945 sodium salt is an orally bioavailable, highly selective and potent CK2 inhibitor, with IC50 values of 1 nM against CK2α and CK2α'.
- GC38419 Cyclovirobuxine D An alkaloid with diverse biological activities
- GC68413 CYH33
- GC63391 CYH33 methanesulfonate CYH33 methanesulfonate is an orally active, highly selective PI3Kα inhibitor with IC50s of 5.9 nM/598 nM/78.7 nM/225 nM against α/β/δ/γ isoform, respectively. CYH33 methanesulfonate inhibits phosphorylation of Akt, ERK and induces significant G1 phase arrest in breast cancer cells and non-small cell lung cancer (NSCLC) cells. CYH33 methanesulfonate has potent activity against solid tumors.
- GC43354 Cysmethynil Post-translational protein prenylation is a 3-step process that occurs at the C-terminus of a number of proteins involved in cell growth control and oncogenesis.
- GC19114 CZ415 CZ415 is a potent and highly selective mTOR inhibitor with a pIC50 of 8.07.
- GC14798 CZC24832 A PI3Kγ inhibitor
- GC18583 D-α-Hydroxyglutaric Acid Over-produced in the human neurometabolic disease D-2-HGA
- GC30056 Danthron (Dantron) Danthron (Dantron) is a natural product extracted from the traditional Chinese medicine rhubarb. Danthron (Dantron) functions in regulating glucose and lipid metabolism by activating AMPK.
- GC15484 Deguelin A potent antiproliferative rotenoid compound
- GC32254 Deltonin Deltonin, a steroidal saponin, isolated from Dioscorea zingiberensis Wright, with antitumor activity; Deltonin inhibits ERK1/2 and AKT activation.
- GC38101 Demethyleneberberine Demethyleneberberine (DMB), as a natural active component of medicinal plant Cortex phellodendri chinensis, has favorable bioactivity.
- GC38482 Desmethylglycitein Desmethylglycitein (4',6,7-Trihydroxyisoflavone), a metabolite of daidzein, sourced from Glycine max with antioxidant, and anti-cancer activities.Desmethylglycitein binds directly to CDK1 and CDK2 in vivo, resulting in the suppresses CDK1 and CDK2 activity. Desmethylglycitein is a direct inhibitor of protein kinase C (PKC)α, against solar UV (sUV)-induced matrix matrix metalloproteinase 1 (MMP1). Desmethylglycitein binds to PI3K in an ATP competitive manner in the cytosol, where it inhibits the activity of PI3K and downstream signaling cascades, leading to the suppression of adipogenesis in 3T3-L1 preadipocytes.
- GN10583 Dihydromyricetin
- GC60782 Disitertide TFA Disitertide (P144) TFA is a peptidic transforming growth factor-beta 1 (TGF-β1) inhibitor specifically designed to block the interaction with its receptor. Disitertide (P144) TFA is also a PI3K inhibitor and an apoptosis inducer.
- GC17837 DMAT A cell-permeable inhibitor of CK2
- GC40561 DNA-PK Inhibitor IV DNA-PK inhibitor IV is an inhibitor of DNA-dependent protein kinase (DNA-PK) with an IC50 value of 400 nM for the DNA-PK-dependent phosphorylation of a p53 peptide substrate.
- GC17243 Dorsomorphin (Compound C) Dorsomorphin (Compound C) (Compound C) is a selective and ATP-competitive AMPK inhibitor (Ki=109 nM in the absence of AMP). Dorsomorphin (Compound C) (BML-275) selectively inhibits BMP type I receptors ALK2, ALK3, and ALK6. Dorsomorphin (Compound C) induces autophagy.
- GC12560 Dorsomorphin (Compound C) 2HCl Dorsomorphin (Compound C) 2HCl (BML-275 dihydrochloride; Compound C dihydrochloride) is a potent, selective and ATP-competitive AMPK inhibitor, with a Ki of 109 nM. Dorsomorphin (Compound C) 2HCl inhibits BMP pathway by targeting the type I receptors ALK2, ALK3, and ALK6. Dorsomorphin (Compound C) 2HCl induces autophagy.
- GC17567 Doxorubicin (Adriamycin) HCl Doxorubicin (Hydroxydaunorubicin) hydrochloride, a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent.
- GC62495 DS-7423 DS-7423 is a dual PI3K and mTOR inhibitor, with IC50 values of 15.6 nM, 34.9 nM for PI3Kα and mTOR, respectively. DS-7423 possesses anti-tumor activity.
- GC33162 Duvelisib R enantiomer (IPI-145 R enantiomer) Duvelisib R enantiomer is a PI3K inhibitor, which is the less active enantiomer of Duvelisib.
- GC39377 EB-3D EB-3D is a potent and selective choline kinase α (ChoKα) inhibitor, with an IC50 of 1 μM for ChoKα1. EB-3D exerts effects on ChoKα expression, AMPK activation, apoptosis, endoplasmic reticulum stress and lipid metabolism. EB-3D exhibits a potent antiproliferative activity in a panel of T-leukemia cell lines. Anti-cancer activity.
- GC43585 eCF309 eCF309 is an ATP-competitive inhibitor of mTOR (IC50 = 15 nM in vitro and in cells) with >65-fold selectivity over other kinases, including PI3Ks.
- GC38330 EHT 5372
- GC38694 Erucic acid A 22carbon monounsaturated fatty acid
- GC38236 Esculetin A coumarin with diverse actions
- GC50072 ETP 45658 Potent PI 3-kinase inhibitor; also inhibits DNA-PK and mTOR
- GC19145 ETP-46321 ETP-46321 is a potent and orally bioavailable PI3Kα and PI3Kδ inhibitor with Kiapps of 2.3 and 14.2 nM, respectively.
- GC10196 ETP-46464 ATR inhibitor,potent and selective
- GC38422 Euphorbiasteroid A tricyclic diterpene
- GC38392 Euscaphic acid Euscaphic acid, a DNA polymerase inhibitor, is a triterpene from the root of the R. alceaefolius Poir. Euscaphic inhibits calf DNA polymerase α (pol α) and rat DNA polymerase β (pol β) with IC50 values of 61 and 108 μM. Euscaphic acid induces apoptosis.
- GC13601 Everolimus (RAD001) A rapamycin derivative
- GC47328 Everolimus-d4 An internal standard for the quantification of everolimus
- GC31411 EX229 A potent and allosteric activator of AMPK
- GC62973 FD223 FD223 is a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor. FD223 displays high potency (IC50=1 nM) and good selectivity over other isoforms (IC50s of 51 nM, 29 nM and 37 nM, respectively for α, β and γ). FD223 exhibits efficient inhibition of the proliferation of acute myeloid leukemia (AML) cell lines by suppressing p-AKT Ser473 thus causing G1 phase arrest during the cell cycle. FD223 has potential for the research of leukemia such as AML.
-
GC13466
Flufenamic acid
TRPC activator
- GC14125 FMK An inhibitor of RSK2